LUDHMILA ABRAHAO HAJJAR

(Fonte: Lattes)
Índice h a partir de 2011
41
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/08 - Laboratório de Anestesiologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: ROBERTO KALIL FILHO × Revista / Livro: Journal of the American College of Cardiology ×

Resultados de Busca

Agora exibindo 1 - 7 de 7
  • conferenceObject
    CARDIOVASCULAR MORTALITY AND MYOCARDIAL INFARCTION AFTER RADIATION THERAPY FOR LEFT VERSUS RIGHT SIDED BREAST CANCER: A META-ANALYSIS
    (2016) BITTENCOURT, Marcio Sommer; VECSEY-NAGY, Milan; SANTOS, Marilia; SILVA, Carolina; FONSECA, Silvia M.; BITTAR, Cristina S.; HOFF, Paulo G.; KALIL-FILHO, Roberto; HAJJAR, Ludhmila A.
  • conferenceObject
    Endovascular Therapeutic Hypothermia Is Feasible as an Adjuvant Therapy in Acute ST-Segment Elevation Myocardial Infarction Patients Without Delay in Door-to-Balloon Time
    (2019) DALLAN, Luis; GIANNETTI, Natali; DAE, Michael; POLASTRI, Thatiane; ROCHITTE, Carlos Eduardo; NOMURA, Cesar Higa; HAJJAR, Ludhmila Abrahao; BERNOCHE, Claudia; LAGE, Silvia; LIMA, Felipe; NICOLAU, Jose Carlos; TAVARES JR., Mucio; RIBEIRO, Expedito; KALIL JR., Roberto; LEMOS, Pedro A.; TIMERMAN, Sergio
  • conferenceObject
    Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial
    (2020) DALLAN, Luis Augusto; GIANNETTI, Natali; ROCHITTE, Carlos Eduardo; POLASTRI, Thatiane; BERNOCHE, Claudia; HAJJAR, Ludhmila Abrahao; LIMA, Felipe; NICOLAU, Jose Carlos; TAVARES JR., Mucio; DAE, Michael; RIBEIRO, Expedito; KALIL JR., Roberto; LEMOS, Pedro A.; TIMERMAN, Sergio
  • conferenceObject
    CARVEDILOL FOR PREVENTION OF CHEMOTHERAPY-INDUCED CARDIOTOXICITY: FINAL RESULTS OF THE PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CECCY TRIAL
    (2020) AYUB-FERREIRA, Silvia M.; AVILA, Monica; BRANDAO, Sara; CRUZ, Fatima D.; WANDERLEY JR., Mauro; RIGAUD, Vagner O. C.; HAJJAR, Ludhmila; KALIL-FILHO, Roberto; CRUZ, Cecilia B. V.; ALVES, Marco Stephan; GUIMARAES, Guilherme V.; ABDUCH, Maria; ISSA, Victor S.; SANTOS, Marilia; BITTENCOURT, Marcio; BOCCHI, Edimar Alcides
  • article 348 Citação(ões) na Scopus
    Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
    (2018) AVILA, Monica Samuel; AYUB-FERREIRA, Silvia Moreira; WANDERLEY JR., Mauro Rogerio de Barros; CRUZ, Fatima das Dores; BRANDAO, Sara Michelly Goncalves; RIGAUD, Vagner Oliveira Carvalho; HIGUCHI-DOS-SANTOS, Marilia Harumi; HAJJAR, Ludhmila Abrahao; KALIL FILHO, Roberto; HOFF, Paulo Marcelo; SAHADE, Marina; FERRARI, Marcela S. M.; COSTA, Romulo Leopoldo de Paula; MANO, Max Senna; CRUZ, Cecilia Beatriz Bittencourt Viana; ABDUCH, Maria Cristina; ALVES, Marco Stephan Lofrano; GUIMARAES, Guilherme Veiga; ISSA, Victor Sarli; BITTENCOURT, Marcio Sommer; BOCCHI, Edimar Alcides
    BACKGROUND Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with beta-blockers remains controversial. OBJECTIVES This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m(2)) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a >= 10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction. RESULTS Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were noted between groups. A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). A nonsignificant trend toward a less-pronounced increase in LV end-diastolic diameter during the follow-up was noted in the carvedilol group (44.1 +/- 3.64 mm to 45.2 +/- 3.2 mm vs. 44.9 +/- 3.6 mm to 46.4 +/- 4.0 mm; p = 0.057). CONCLUSIONS In this largest clinical trial of beta-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the authors noted a 13.5% to 14.5% incidence of cardiotoxicity. In this scenario, carvedilol had no impact on the incidence of early onset of LVEF reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.(Carvedilol Effect in Preventing Chemotherap-Induced Cardiotoxicity [CECCy] NCTO1724450)(C) 2018 by the American College of Cardiology Foundation.
  • conferenceObject
    T1 MAPPING AND MYOCARDIUM STRAIN EVALUATED THROUGH TISSUE TRACKING IN PATIENTS WITH LYMPHOMA TREATED WITH ANTHRACYCLINES
    (2020) COSTA, Isabela; LEAL, Bruna; CRUZ, Cecilia; PEREIRA, Juliana; ROCHITTE, Carlos Eduardo; KALIL FILHO, Roberto; HAJJAR, Ludhmila Abrahao
  • conferenceObject
    REAL-LIFE EXPERIENCE OF TRASTUZUMAB USE AMONG 806 BREAST CANCER PATIENTS: ROLE OF ROUTINE SERIAL ECHOCARDIOGRAPHY FOR THE EVALUATION OF ASYMPTOMATIC VENTRICULAR DYSFUNCTION IN THE FIRST 6 MONTHS OF TRASTUZUMAB THERAPY
    (2019) SILVA, Carolina M. P. D. Carvalho; BITTENCOURT, Marcio; SANTOS, Marilia; BITTAR, Cristina; FONSECA, Silvia; PINTO, Giovanni; COSTA, Isabela; FIGUEIREDO, Clara; SIQUEIRA, Julio; BOND, Marina; NETO, Paulo; GONZALEZ, Thalita; TESTA, Laura; HOFF, Paulo; KALIL-FILHO, Roberto; HAJJAR, Ludhmila